HER2-LOW BREAST CANCER

This study is testing whether a new drug called BL-M07D1 works better than standard chemotherapy for people with advanced HER2-low breast cancer that has returned or spread. It will involve about 566 participants who will be randomly assigned to receive either the new drug or a c…

This study is observing how well the drug trastuzumab-rezetecan works and how safe it is for people with HER2-positive or HER2-low breast cancer in real-world medical settings. It will follow 300 patients who are already scheduled to receive this treatment as part of their regula…

This study aims to understand how well the drug trastuzumab deruxtecan works and what side effects patients experience in real-world medical settings in China. It will follow 800 adults with advanced breast cancer that has spread and is difficult to remove surgically. Researchers…

This study is testing whether switching between two newer cancer drugs can help control advanced breast cancer that has spread and stopped responding to a similar prior treatment. It will involve about 357 people with HER2-negative metastatic breast cancer. The main goal is to se…

This study is testing whether two existing cancer drugs work better together for people with advanced HER2-low breast cancer whose disease has worsened despite previous treatment. The trial will enroll 37 patients to receive both disitamab vedotin and bevacizumab, monitoring how …

This study is testing a new type of PET scan to see if it can better identify which patients with advanced breast cancer are likely to benefit from a specific targeted drug called T-DXd. The scan looks for a protein called HER2 on cancer cells. Researchers hope this more precise …

This study aims to understand the genetic makeup of a specific type of breast cancer called HER2-low. Researchers will observe 255 Chinese women with this cancer to see how often certain gene changes occur and if these changes are linked to how long patients live or if the cancer…